These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18592356)

  • 1. Lipid-based formulations for danazol containing a digestible surfactant, Labrafil M2125CS: in vivo bioavailability and dynamic in vitro lipolysis.
    Larsen A; Holm R; Pedersen ML; Müllertz A
    Pharm Res; 2008 Dec; 25(12):2769-77. PubMed ID: 18592356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solution or suspension - Does it matter for lipid based systems? In vivo studies of chase dosing lipid vehicles with aqueous suspensions of a poorly soluble drug.
    Larsen AT; Holm R; Müllertz A
    Eur J Pharm Biopharm; 2017 Aug; 117():308-314. PubMed ID: 28465239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a nanoemulsion formulation strategy for oral bioavailability enhancement of danazol in rats and dogs.
    Devalapally H; Silchenko S; Zhou F; McDade J; Goloverda G; Owen A; Hidalgo IJ
    J Pharm Sci; 2013 Oct; 102(10):3808-15. PubMed ID: 23878097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs.
    Cuiné JF; Charman WN; Pouton CW; Edwards GA; Porter CJ
    Pharm Res; 2007 Apr; 24(4):748-57. PubMed ID: 17372700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs.
    Cuiné JF; McEvoy CL; Charman WN; Pouton CW; Edwards GA; Benameur H; Porter CJ
    J Pharm Sci; 2008 Feb; 97(2):995-1012. PubMed ID: 18064698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability.
    Childs SL; Kandi P; Lingireddy SR
    Mol Pharm; 2013 Aug; 10(8):3112-27. PubMed ID: 23822591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Stealth' lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug.
    Feeney OM; Williams HD; Pouton CW; Porter CJ
    J Control Release; 2014 Oct; 192():219-27. PubMed ID: 25058571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Impact of Surfactant Type and Digestion: Highly Digestible Surfactants Improve Oral Bioavailability of Nilotinib.
    Koehl NJ; Holm R; Kuentz M; Jannin V; Griffin BT
    Mol Pharm; 2020 Sep; 17(9):3202-3213. PubMed ID: 32649208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.
    Anby MU; Nguyen TH; Yeap YY; Feeney OM; Williams HD; Benameur H; Pouton CW; Porter CJ
    Mol Pharm; 2014 Nov; 11(11):4069-83. PubMed ID: 25265395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of cyclodextrin concentration on the oral bioavailability of danazol and cinnarizine in rats.
    Holm R; Olesen NE; Hartvig RA; Jørgensen EB; Larsen DB; Westh P
    Eur J Pharm Biopharm; 2016 Apr; 101():9-14. PubMed ID: 26776271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of Solid Self-Emulsifying Formulation for Improving the Oral Bioavailability of Erlotinib.
    Truong DH; Tran TH; Ramasamy T; Choi JY; Lee HH; Moon C; Choi HG; Yong CS; Kim JO
    AAPS PharmSciTech; 2016 Apr; 17(2):466-73. PubMed ID: 26238806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation.
    Porter CJ; Kaukonen AM; Boyd BJ; Edwards GA; Charman WN
    Pharm Res; 2004 Aug; 21(8):1405-12. PubMed ID: 15359575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier.
    Van Speybroeck M; Williams HD; Nguyen TH; Anby MU; Porter CJ; Augustijns P
    Mol Pharm; 2012 Sep; 9(9):2750-60. PubMed ID: 22870936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kolliphor surfactants affect solubilization and bioavailability of fenofibrate. Studies of in vitro digestion and absorption in rats.
    Berthelsen R; Holm R; Jacobsen J; Kristensen J; Abrahamsson B; Müllertz A
    Mol Pharm; 2015 Apr; 12(4):1062-71. PubMed ID: 25679417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestion.
    Anby MU; Williams HD; Feeney O; Edwards GA; Benameur H; Pouton CW; Porter CJ
    Pharm Res; 2014 Jun; 31(6):1536-52. PubMed ID: 24477676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats.
    Dahan A; Hoffman A
    Eur J Pharm Biopharm; 2007 Aug; 67(1):96-105. PubMed ID: 17329087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Insights into Using Lipid Based Suspensions for 'Brick Dust' Molecules: Case Study of Nilotinib.
    Koehl NJ; Holm R; Kuentz M; Griffin BT
    Pharm Res; 2019 Feb; 36(4):56. PubMed ID: 30796596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo evaluations of the performance of an indirubin derivative, formulated in four different self-emulsifying drug delivery systems.
    Heshmati N; Cheng X; Dapat E; Sassene P; Eisenbrand G; Fricker G; Müllertz A
    J Pharm Pharmacol; 2014 Nov; 66(11):1567-75. PubMed ID: 24961657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simplified method to screen for in-vivo performance of oral lipid formulations.
    Kilic M; Dressman J
    J Pharm Pharmacol; 2014 May; 66(5):615-23. PubMed ID: 24313318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of an in vitro lipolysis model to evaluate type I lipid formulations].
    Liu Y; Yi T; Huan D; Xiao L; He JK
    Yao Xue Xue Bao; 2010 Oct; 45(10):1307-11. PubMed ID: 21348311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.